Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;47(3):833-6.
doi: 10.1128/JCM.01464-08. Epub 2008 Dec 30.

Evaluation of a highly sensitive qualitative human immunodeficiency virus type 1 (HIV-1) RNA assay for detection of HIV-1 suppression

C Thomas Nugent  1 , Vladislav Nodelman, Cristina Giachetti, Douglas D Richman, David J Looney
Affiliations

Evaluation of a highly sensitive qualitative human immunodeficiency virus type 1 (HIV-1) RNA assay for detection of HIV-1 suppression

C Thomas Nugent et al. J Clin Microbiol. 2009 Mar.

Abstract

By using a mathematical model, the APTIMA human immunodeficiency virus type 1 (HIV-1) RNA qualitative assay was evaluated as a semiquantitative assay to distinguish HIV-1 patient samples needing quantitation from samples in which the virus was suppressed with antiretroviral therapy.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Effect of the S/COtest value on sensitivity and specificity. Results from the first study were used to generate the regression model and lower 99% PI as described in the text. The graph in panel A was overlaid with results from the masked study with additional specimens to verify the model. Panel B focuses on the area where the S/CO value is set to maximum sensitivity (sens.). adjR2, adjusted R2 value; spec., specificity.
See this image and copyright information in PMC

References

    1. Caliendo, A. M., J. Ingersoll, A. M. Green, F. S. Nolte, and K. A. Easley. 2004. Comparison of the sensitivities and viral load values of the AMPLICOR HIV-1 MONITOR version 1.0 and 1.5 tests. J. Clin. Microbiol. 425392-5393. - PMC - PubMed
    1. Egger, M., M. May, G. Chêne, A. N. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D'Arminio Monforte, F. de Wolf, P. Reiss, J. D. Lundgren, A. C. Justice, S. Staszewski, C. Leport, R. S. Hogg, C. A. Sabin, M. J. Gill, B. Salzberger, J. A. Sterne, and the ART Cohort Collaboration. 2002. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360119-129. - PubMed
    1. Galli, R., L. Merrick, M. Friesenhahn, and R. Ziermann. 2005. Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens. J. Clin. Virol. 34245-252. - PubMed
    1. Reference deleted.
    1. Havlir, D. V., R. Bassett, D. Levitan, P. Gilbert, P. Tebas, A. C. Collier, M. S. Hirsch, C. Ignacio, J. Condra, H. F. Günthard, D. D. Richman, and J. K. Wong. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286171-179. - PubMed

Publication types